Ackman: Valeant Will Not Overpay for Salix -CNBC
13 Março 2015 - 4:40PM
Dow Jones News
Activist investor Bill Ackman, who holds a 5% stake in Valeant
Pharmaceuticals International Inc. (VRX.T), on Friday said the drug
company will not overpay in its effort to acquire Salix
Pharmaceuticals Ltd. (SLXP), despite a competing offer from Endo
International PLC.
Valeant Chief Executive J. Michael Pierson "is the most
disciplined buyer of companies. He's not going to overpay for
Salix," Mr. Ackman said in an interview on CNBC. "I don't view it
(Endo offer) as a credible bid," he said.
Web site: www.cnbc
Write to nymonitoring@dowjones.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Salix (NASDAQ:SLXP)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Salix (NASDAQ:SLXP)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Salix Pharmaceuticals Ltd.